Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells

Diabetes, Obesity and Metabolism

Volumn 12, Issue 2, 2010, Pages 148-157

  Benhaddou Andaloussi, A ^a   Martineau, L C ^a   Vallerand, D ^a   Haddad, Y ^a   Afshar, A ^a   Settaf, A ^b   Haddad, P S ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

3T3 L1 adipocytes; Akt protein kinase B; AMP activated protein kinase; C2C12 skeletal muscle cells; H4IIE hepatocytes; Intracellular signalling; Mitochondrial respiration; Peroxisome proliferator activated receptor ; Type 2 diabetes mellitus; Uncoupling

Indexed keywords

CARVACROL; HEDERAGENIN; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NIGELLA SATIVA EXTRACT; NIGELLIMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; ROSIGLITAZONE; THYMOL; THYMOQUINONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INSULIN LIKE ACTIVITY; LIVER CELL; LIVER MITOCHONDRION; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; RAT; REPORTER GENE; SKELETAL MUSCLE;

EID: 73349091554     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01131.x     Document Type: Article

References (59)

1. Fact sheet N°312. 2006, WHO
2. Del Prato S, Bianchi C, Marchetti P. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev 2007, 23:518-527.
3. Leverve XM, Guigas B, Detaille D. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003, 29:6S88-6S94.
4. Misra P, Chakrabarti R. The role of AMP kinase in diabetes. Indian J Med Res 2007, 125:389-398.
5. Gelman L, Feige JN, Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta 2007, 1771:1094-1107.
6. Alarcon-Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S. Study of the anti-hyperglycemic effect of plants used as antidiabetics. J Ethnopharmacol 1998, 61:101-110.
7. Yeh GY, Eisenberg DM, Kaptchuk TJ. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003, 26:1277-1294.
8. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents. Phytomedicine 1995, 2:137-189.
9. Cheng Z, Pang T. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 2006, 1760:1682-1689.
10. Tan MJ, Ye JM, Gu M. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008, 15:263-273.
11. Yin J, Zhang H, Turner N. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008, 8:99-111.
12. Bellakhdar J, Claisse R, Fleurantin J. Repertory of standard herbal drugs in the Moroccan pharmacopoea. J Ethnopharmacol 1991, 35:123-43.
13. Ziyyat A, Legssyer A, Mekhfi H. Phytotherapy of hypertension and diabetes in oriental Morocco. J Ethnopharmacol 1997, 58:45-54.
14. Haddad PS, Depot M, Settaf A. Use of antidiabetic plants in Morocco and Quebec. Diabetes Care 2001, 24:608-609.
15. Al-Awadi FM, Khattar MA, Guamaa KA. On the mechanism of the hypoglycaemic effect of a plant extract. Diabetologia 1985, 28:432-434.
16. Al-Awadi FM, Gumaa KA. Studies on the activity of the individual plants of an antidiabetic plant mixture. Acta Diabetoogia Latina 1987, 24:37-41.
17. Al-Awadi FM, Fatania H, Shamte U. The effect of a plants mixture extract on liver gluconeogenesis in streptozotocin-induced diabetic rats. Diabetes Research 1991, 18:168.
18. Al-Hader A, Aquel M, Hasan Z. Hypoglycemic effects of the volatile oil of Nigella sativa seeds. International Journal of Pharmacology 1993, 31:96-100.
19. Labhal A, Settaf A, Zalagh F. Propriétés anti-diabétiques des graines de Nigella sativa chez le Meriones shawi obèse et diabétique. Espérance Médicale 1999, 47:72-74.
20. Meral I, Yener Z, Kahraman T. Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. J Vet Med A Physiol Pathol Clin Med 2001, 48:593-599.
21. El-Dakhakhny M, Mady N, Lembert N. The hypoglycemic effect of Nigella sativa oil is mediated by extrapancreatic actions. Planta Medica 2002, 68:465-466.
22. Fararh KM, Atoji Y, Shimizu Y. Insulinotropic properties of Nigella sativa oil in streptozotocin plus nicotinamide diabetic hamster. Research in Veterinary Science 2002, 73:279-282.
23. Zaoui A, Cherrah Y, Alaoui K. Effects of Nigella sativa fixed oil on blood homeostasis in rat. Journal of Ethnopharmacology 2002, 79:23-26.
24. Kanter M, Meral I, Yener Z. Partial Regeneration/Proliferation of the β-Cells in the Islets of Langerhans by Nigella sativa L. in Streptozotocin-Induced Diabetic Rats. Tohoku J Exp Med 2003, 201:213-219.
25. Fararh KM, Atoji Y, Shimizu Y. Mechanisms of the hypoglycaemic and immunopotentiating effects of Nigella sativa L. oil in streptozotocin-induced diabetic hamsters. Res Vet Sci 2004, 77:123-129.
26. Kanter M, Coskum O, Korkmaz A. Effects of Nigella sativa on oxidative stress and beta-cell damage in streptozocin-induced diabetic rats. Anat Rec A Discov Mol Cell Evol Biol 2004, 279:685-691.
27. Le PM, Benhaddou-Andaloussi A, Spoor D. The petroleum ether extract of Nigella sativa exerts lipid-lowering and insulin-sensitizing actions in the rat. J Ethnopharmacol 2004, 94:251-259.
28. Rchid H, Chevassus H, Nmila R. Nigella sativa seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. Fundam Clin Pharmacol 2004, 18:525-529.
29. Haddad PS, Martineau LC, Lyoussi B, Soumyanath A. Antibiabetic plants of North Africa and the Middle East. Traditional Medicines for Modern Times: Antibiabetic Plants 2006, 221-242. In:, ed., Boca Raton, FL, CRC Press
30. Benhaddou-Andaloussi A, Martineau LC, Spoor D. Antidiabetic activity of Nigella sativa seed extract in cultured pancreatic cells, skeletal muscle, and adipocytes. Pharm Biol 2008, 46:96-104.
31. Basha LIA, Rashed MS, Aboul-Enein HY. Dithymoquinone and thymol. TLC assay of thymoquinone in black seed oil (Nigella sativa linn) and identification of dithymoquinone and thymol. J Liq Chromatogr 1995, 18:105-115.
32. Michelitsch A, Rittmannsberger A, Hufner A. Determination of isopropylmethylphenols in black seed oil by differential pulse voltammetry. Phytochem Anal 2004, 15:320-324.
33. Mustafa Z, Soliman G. Melanthegenin and its identity with hederagenin. J Chem Soc 1943, 43:70-70.
34. Atta-ur-Rahman MS, Zaman K. Nigellimine: a new isoquinoline alkaloid from the seeds of Nigella sativa. J Nat Prod 1992, 55:676-678.
35. Spoor DC, Martineau LC, Leduc C. Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential. Can J Physiol Pharmacol 2006, 84:847-858.
36. Chaung WW, Jacob A, Ji Y. Suppression of PGC-1alpha by ethanol: implications of its role in alcohol induced liver injury. Int J Clin Exp Med 2008, 1:161-170.
37. Johnson D, Lardy H. Isolation of liver and kidney mitochondria. Methods in Enzymology 1967, 94-96. vol. 10., New York, Academic Press
38. Ligeret H, Brault A, Vallerand D. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol 2008, 115:507-514.
39. Morin D, Hauet T, Spedding M. Mitochondria as target for antiischemic drugs. Adv Drug Deliv Rev 2001, 49:151-174.
40. Schornack PA, Gillies RJ. Contributions of cell metabolism and H + diffusion to the acidic pH of tumors. Neoplasia 2003, 5:135-145.
41. Gerber E, Bredy A, Kahi R. Enhancement of glycolysis and CO2 formation from glycerol by hydroxyl radical scavengers in rat hepatocytes. Res Commun Mol Pathol Pharmacol 1996, 94:63-71.
42. Tirosh A, Rudich A, Bashan N. Regulation of glucose transporters-implications for insulin resistance states. J Pediatr Endocrinol Metab 2000, 13:115-133.
43. Wu C, Okar DA, Kang J. Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:51-59.
44. Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci 2008, 9:478-492.
45. Hayashi T, Hirshman MF, Kurth EJ. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998, 47:1369-1373.
46. Bergeron R, Previs SF, Cline GW. Effect of 5-amino-imidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001, 50:1076-1082.
47. Rossmeisl M, Flachs P, Brauner P. Role of energy charge and AMP-activated protein kinase in adipocytes in the control of body fat stores. Int J Obes Relat Metab Disord 2004, 28((Suppl. 4)):S38-S44.
48. Wheeler MH, Camp BJ. Inhibitory and uncoupling actions of extracts from Karwinskia humboldtiana on respiration and oxidative phosphorylation. Life Sci II 1971, 10:41-51.
49. Toyomizu M, Okamoto K, Ishibashi T. Uncoupling effect of anacardic acids from cashew nut shell oil on oxidative phosphorylation of rat liver mitochondria. Life Sci 2000, 66:229-234.
50. Polya G. Biochemical Targets of Plant Bioactive Compounds: A Pharmacological Reference Guide to Sites of Action and Biological Effects 2003, Boca Raton, FL, Taylor & Francis.
51. Alberti KG. The biochemical consequences of hypoxia. J Clin Pathol Suppl (R Coll Pathol) 1977, 11:14-20.
52. Khan MA. Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharmacology 1999, 7:15-35.
53. Terada H. Uncouplers of oxidative phosphorylation. Environ Health Perspect 1990, 87:213-218.
54. Badary OA, Abdel-Naim AB, Abdel-Wahab MH. The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology 2000, 143:219-226.
55. El-Saleh SC, Al-Sagair OA, Al-Khalaf MI. Thymoquinone and Nigella sativa oil protection against methionine-induced hyperhomocysteinemia in rats. Int J Cardiol 2004, 93:19-23.
56. Khattab MM, Nagi MN. Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. Phytother Res 2007, 21:410-414.
57. Belzacq AS, Vieira HL, Kroemer G. The adenine nucleotide translocator in apoptosis. Biochimie 2002, 84:167-176.
58. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 2005, 5:1749-1770.
59. Girard J. Mechanisms of action of thiazolidinediones. Diabetes Metab 2001, 27:271-278.